Consensus Veradigm Inc.

Equities

MDRX

US01988P1084

Market Closed - OTC Markets Other stock markets 03:59:59 2024-04-19 pm EDT			5-day change	1st Jan Change
7.6 ^USD	+0.66%		-1.30%	-27.55%

Apr. 03	Veradigm and Vim Announce Strategic Collaboration to Improve Payer-Provider Collaboration	CI
Mar. 19	Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15	MT

Evolution of the average Target Price on Veradigm Inc.

Price target over the last 5 years

History of analyst recommendation changes

0e2b2ab228bc1b17fb20c1c9c949fa.XVOp3Vz0N4HgHtlGEWYn3ILLHE4_yqgzUB2nGg1Wx9E.BCDhtGqbccONLO4eRV5TmsupXxdIoPxRHVLXYntnoIZqEc-7NLcEzNkmjA~686e5b25e55b4eb78071ec12fecbccad

Analyst Recommendations on Veradigm Inc.

Deutsche Bank Downgrades Veradigm to Hold From Buy, Adjusts Price Target to $10 From $15	Mar. 19	MT
RBC Halves Price Target on Veradigm to $11 From $22, Keeps Outperform Rating	Jan. 19	MT
Barclays Starts Allscripts Healthcare Solutions With Equalweight Rating, $11 Price Target	Jan. 03	MT
Deutsche Bank Adjusts Veradigm Price Target to $15 From $18, Maintains Buy Rating	Dec. 11	MT
Argus Research Downgrades Allscripts Healthcare Solutions to Hold From Buy	23-07-06	MT
Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $18 From $21, Maintains Buy Rating	23-06-30	MT
Stephens Initiates Allscripts Healthcare Solutions at Equalweight With $13 Price Target	23-04-12	MT
Piper Sandler Downgrades Veradigm to Neutral From Overweight, Adjusts Price Target to $18.50 From $17	23-02-01	MT
JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating	22-11-18	MT
Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Price Target to $23 From $22	22-11-09	MT
Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Maintains Buy Rating	22-11-07	MT
Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $26, Maintains Buy Rating	22-10-06	MT
KeyBanc Initiates Coverage on Allscripts Healthcare Solutions With Sector Weight Rating	22-09-16	MT
Goldman Sachs Starts Allscripts Healthcare Solutions at Neutral With $21 Price Target	22-07-12	MT
Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $19, Maintains Neutral Rating	22-06-10	MT
Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $22 From $19, Maintains Neutral Rating	22-03-18	MT
Deutsche Bank Lifts Allscripts Healthcare Solutions to Buy From Hold, Price Target to $26 From $20	22-03-04	MT
SVB Leerink Adjusts Allscripts Healthcare Solutions' Price Target to $24 from $22, Keeps Outperform Rating	22-03-03	MT
SVB Leerink Upgrades Allscripts Healthcare Solutions to Outperform from Market Perform, Adjusts Price Target to $22 from $19	22-01-25	MT
Piper Sandler Adjusts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Neutral Rating	22-01-25	MT
Deutsche Bank Adjusts Allscripts Healthcare Solutions PT to $20 From $18, Maintains Hold Rating	21-11-23	MT
Canaccord Genuity Adjusts Price Target on Allscripts Healthcare Solutions to $21 From $18, Keeps Buy Rating	21-11-08	MT
ALLSCRIPTS HEALTHCARE : RBC Lifts Price Target on Allscripts Healthcare Solutions to $19 From $17, Maintains Outperform Rating	21-08-06	MT
ALLSCRIPTS HEALTHCARE : Deutsche Bank Adjusts Price Target on Allscripts Healthcare Solutions to $17 From $15, Maintains Hold Rating	21-05-20	MT
ALLSCRIPTS HEALTHCARE : Argus Downgrades Allscripts Healthcare Solutions to Hold From Buy	21-03-02	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.55 USD

Average target price

15 USD

Spread / Average Target

+98.68%

High Price Target

26 USD

Spread / Highest target

+244.37%

Low Price Target

10 USD

Spread / Lowest Target

+32.45%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Veradigm Inc.

Deutsche Bank Securities
RBC Capital Markets
Barclays
Argus
Stephens Inc.
Piper Sandler
JPMorgan Chase
Goldman Sachs
KeyBanc Capital Markets
SVB Leerink
Canaccord Genuity
UBS

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar